PersonFounderInvestor
Omri Amirav-Drory
Omri Amirav-Drory, Ph.D., is an Israeli-American scientist, serial entrepreneur, and General Partner at NFX, a $1.4B AUM venture firm. A Fulbright postdoc at Stanford (Axel Brunger's lab), he co-founded Genome Compiler — acquired by Twist Bioscience in 2016 — then turned to investing through NFX Bio, backing scientist-founders at the intersection of technology and biology. In 2022 he co-founded Renewal Bio with Prof. Jacob Hanna to commercialize synthetic embryo technology for longevity and regenerative medicine. His overarching thesis — 'The Race to 160' — frames aging as the defining solvable problem of our time.
venture capitalbiotechsynthetic biologylongevitynfxnfx bio
